Association of FGFR1 with ER-alpha maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer by Formisano, Luigi
UNIVERSITÀ DEGLI STUDI DI NAPOLI 
“FEDERICO II” 
 
 
 
 
 
 
DOTTORATO DI RICERCA 
IN 
TERAPIE AVANZATE MEDICO-CHIRURGICHE 
XXIX CICLO 
 
 
 
 
 
Tesi Sperimentale di Dottorato 
Association of FGFR1 with ER maintains ligand-
independent ER transcription and mediates resistance to 
estrogen deprivation in breast cancer 
 
 
 
 
 
 
 
 
RELATORE              CANDIDATO 
Chiar.mo/a             Dott. Luigi Formisano 
Prof. Sabino De Placido     
 1 
INTRODUCTION 
 
Amplification of the chromosomal region 8p11-12, the genomic location of fibroblast growth 
factor receptor 1 (FGFR1), has been reported in breast, ovarian, bladder, lung and oral squamous 
cancers, and in rhabdomyosarcoma (1-7). FGFR1 amplification occurs in ~10% of patients with 
ER+/HER2-negative breast cancer where it is associated with early relapse following adjuvant 
tamoxifen therapy and with poor survival (8). Blockade of FGFR1 signalling by pharmacological or 
genetic approaches in human breast cancer cells harboring FGFR1 amplification leads to decreased 
cell growth and survival, suggesting FGFR1 gene amplification is a surrogate of cancer cell 
dependence on aberrant FGFR activity (8). 
FGFRs belong to the family of receptor tyrosine kinases (RTKs) that consist of an extracellular 
ligand-binding domain linked to an intracellular catalytic protein kinase core via a single-pass 
transmembrane domain (TMD) (9). Binding of FGF ligands induces receptor dimerization, activation 
of the kinase domain and phosphorylation of C-terminal tyrosines to which adaptor proteins dock, 
followed by activation of signal transduction pathways, including PI3K/AKT, 
RAS/RAF/MEK/ERK, phospholipase CPLC and STATs (10). In addition, there is strong 
evidence that FGFRs traffic to the nucleus, where they may function in a different manner to classic 
transmembrane RTKs (11). For example, nuclear FGFR3 has been shown in the nucleus of malignant 
and non-malignant breast epithelial cells (12). A nuclear interaction of FGFR2, STAT5 and 
progesterone receptor (PR), associated with PR/STAT5-regulated gene expression and breast cancer 
progression was also reported (13). Other studies have reported nuclear localization and a nucleus-
specific function of FGFR1 in non-mammary cells (14-17). Medulloblastoma cells transfected with 
FGFR1-eGFP and evaluated by immunofluorescence have shown FGFR1 is associated with cell 
membranes, cytosol and nuclear compartments (17). Substitution of the atypical TMD of FGFR1 (β-
sheet containing polar amino acids) with the typical TMD of FGFR4 (helical, hydrophobic) 
prevents the nuclear localization of FGFR1 (18). Inability of both the full-length and cleaved forms 
of FGFR1 to localize to the nucleus results in reduced migration and invasiveness of cancer cells (15, 
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16). Finally, ChIP-seq studies revealed that FGFR1 binds nuclear transcription factors involved in 
neural and muscle development (19).  
Amplification of the FGF3/4/19 ligand genes on chromosome 11q12-14 occurs in ~15% of 
human breast cancers (20, 21). Notably, one-third of FGFR1-amplified tumors also harbor 
amplification of CCND1, FGF3, FGF4 and FGF19 (22). This co-amplification has been associated 
with resistance to estrogen deprivation in ER+ breast cancer and poor patient outcome (22), 
suggesting the possibility of ligand-receptor cooperativity. 
Herein, we investigated the mechanisms by which FGFR1 amplification confers resistance to 
antiestrogen therapy in ER+ breast cancers. In a cohort of patients treated with the aromatase inhibitor 
letrozole, we observed that ER+ cancers with concurrent FGFR1 and FGF3/4/19 amplification 
maintained their proliferation despite drug-induced estrogen deprivation and exhibited nuclear 
localization of FGFR1. We hypothesized that aberrant FGFR1 signalling is causally associated with 
resistance to estrogen deprivation. Indeed, we show herein that estrogen deprivation leads to an 
increase of total and nuclear FGFR1 expression as well as FGF3/4/19 ligand expression. We also 
provide evidence that FGFR1 couples with ERα to drive estrogen-independent transcription of ERα-
responsive genes. Finally, we show that dual pharmacological inhibition of FGFR1 and ERα can 
reduce the growth of patient-derived ER+/FGFR1-amplified xenografts. We propose this physical 
interaction between FGFR1 and ER provides a mechanistic explanation for how FGFR1 
amplification contributes to endocrine therapy resistance and poor outcome of patients with ER+ 
breast cancer. 
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METHODS 
Clinical trial and tumor biopsies. Tumor samples were obtained from patients with stage I-III 
operable ER+/HER2– breast cancer enrolled in a clinical trial of the aromatase inhibitor letrozole 
administered for 2 weeks prior to surgery (NCT00651976) (23). Patients provided written informed 
consent according to a protocol approved by the Vanderbilt-Ingram Cancer Center Institutional 
Review Board. Intra-operative biopsies or surgical specimens, snap-frozen in liquid nitrogen and 
formalin-fixed paraffin-embedded (FFPE), were obtained from each patient’s tumor. 
Immunohistochemistry (IHC) was conducted in both the pretreatment biopsy and in the post-
treatment surgical biopsy of both tumors for Ki67 (Dako #M7240), ER (Santa Cruz #sc542) and PR 
(Dako #M3569). IHC for ER and PR was conducted according to methods reported elsewhere (24). 
FFPE tumor sections were scanned at 100x magnification, and the area containing the highest number 
of positive cells was selected. Positive and negative tumor cells were manually counted at 400x; the 
percentage of positive cells was calculated with at least 1,000 viable cells. Ki67 IHC was scored by 
two independent pathologists (MVE and JMG).  
Cell Lines. Cell lines were obtained from ATCC and maintained in DMEM/10% fetal bovine serum 
(FBS; Gibco). Long-term estrogen-deprived (LTED) cells were generated upon long-term culture in 
phenol red-free IMEM/10% dextran-charcoal-treated FBS [DCC-FBS; Hyclone, contains <0.0367 
pM 17β-estradiol (E2)] for 3-8 months until exponentially-growing, hormone-independent cells 
emerged as described previously (25). Cell lines were authenticated by ATCC prior to purchase by 
the STR method. Cell lines were not authenticated after purchase. Mycoplasma testing was conducted 
for each cell line before use. All experiments were performed less than 2 months after thawing early 
passage cells. 
FGFR1 and CCND1 fluorescence in situ hybridization (FISH) analysis. Four-μm tissue sections 
were mounted on charged slides and hybridized overnight with the SPEC FGFR1/CEN8 Dual Color 
Probe (ZytoVision, catalog# Z-2072-200) and CCND1/CEN11 Dual Color Probe (ZytoVision, 
catalog# Z-2071-200). Briefly, deparaffinization, protease treatment and washes were performed as 
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per standard protocols. After this pretreatment, the slides were denatured in the presence of 10 μL of 
the probe for 6 min at 72°C, and hybridized at 37°C overnight in StatSpin (Thermobrite, Abbott 
Molecular, Inc.). Post-hybridization saline-sodium citrate washes were performed at 72°C and the 
slides were then stained with DAPI before analysis. Normal vessels, fibroblasts and/or non-tumor 
tissues served as internal positive controls. Cases were further evaluated only if diploid nuclei in 
normal tissues displayed one or two clearly distinct signals of each color. Tumor tissue was scanned 
for amplification hot spots under 40× magnification (Olympus BX60 Fluosescent microscope). If the 
FGFR1 or CCND1 signals were homogeneously distributed, then random areas were used for 
counting the signals. Twenty to sixty tumor cell nuclei from random areas were individually 
evaluated with the 100× oil immersion objective by counting green FGFR1 and orange centromere 
8 (for FGFR1), or orange CCND1 and green centromere 11 (for CCND1) signals. The FGFR1/CEN8 
or CCND1/CEN11 ratio and the average FGFR1 or CCND1 copy number per cell were calculated 
next. Cases were considered to be FGFR1 or CCND1 amplified under one of the following 
conditions: 
a) FGFR1/CEN8 or CCND1/CEN11 ratio ≥2.0; 
b) average number of FGFR1 or CCND1 signals per tumor cell nucleus ≥6 
Cell proliferation. Cells were plated in 10% DCC-FBS ± FGF3 100 ng/mL or ± 2 µM lucitanib for 
7 or 14 days before being trypsinized and counted using a Coulter Counter (Beckman Coulter), or 
fixed and stained with crystal violet followed by quantification by spectrophotometric detection at 
490 nm using a plate reader (GloMax®-Multi Detection System, Promega). Clonogenic assays. Cells 
(5x104 /well) were seeded in triplicate in medium with 10% DCC-FBS in 6-well plates and then 
treated with ± 100 ng/mL FGF3 ± 2 µM lucitanib or 1 µM ICNB054828. Media, FGF ligands, and 
drugs were replenished every 3 days until 50-70% confluency was observed in control wells. 
Monolayers were then fixed and stained with 20% methanol/80% water/0.5% crystal violet for 20 
min, washed with water, and dried. After photographic images of the plates were obtained, the crystal 
violet stain was solubilized with 20% acid acetic and the image intensity of the monolayers was 
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quantified by spectrophotometric detection at 490 nm using a plate reader (GloMax®-Multi 
Detection System, Promega).  siRNA transfection experiments. Cells were reverse transfected into 
100-mm dishes using Lipofectamine RNAiMAX® (Invitrogen) and 25 nM siRNA [siControl- 
Ambion cat. #4390843; siFGFR1- Ambion cat. #AM16708; siFGFR1- Ambion cat. #AM51331]. 
The next day, 5x104 cells/well were reseeded in IMEM/10% DCC-FBS in 6-well plates for 
proliferation assays or in 60-mm plates for immunoblot analysis. For proliferation assays, media was 
changed 72 h after transfection to IMEM/10% DCC-FBS + 100 ng/mL FGF3 and every 3 days 
thereafter. Cells were trypsinized 7 days post-transfection and counted using a Coulter Counter 
(Beckman Coulter). For immunoblot analyses, cells were harvested and protein lysates prepared on 
day 3 post-transfection. Three-dimensional Matrigel culture. Cells (~1x104 /well) were seeded in 48-
well plates in triplicate. Before seeding, cells were suspended in their respective medium on growth 
factor–reduced Matrigel (BD Biosciences) as described previously (26). Ligands and/or inhibitors 
were added at the time of cell seeding and replenished with fresh medium every 3 days. After 6 or 
12 days, images were captured from at least 3 different fields using a CK 40 microscope. Cell 
viability was measured by MTT assay and the number of colonies per well was quantified by 
Gelcount® scanning. 
Proximity ligation assay (PLA). FGFR1 expression and localization. PLA was performed using 
FGFR1 (Abcam, cat. #10646, rabbit) antibody. Cells (5x104 /well) were seeded in 16-well chamber 
slides (Lab-Tek) in triplicate in their respective growth medium and then serum-starved for 24 h. 
PLA was performed as per the Duolink in situ PLATM protocol (Olink Bioscience, Sweden). To 
visualize the bound antibody pairs, the Duolink Detection Kit (#DUO92101 –Sigma) with PLA plus 
and minus probes for rabbit (anti-rabbit plus #DUO92002, anti-rabbit minus #DUO92005 -Sigma for 
FGFR1) were used according to the manufacturer’s protocol. Slides were mounted with the Duolink 
Mounting Medium and stained with DAPI (82040-0005). Analysis was performed by confocal 
microscopy (LSM710, ZEISS) and the number of red dots (FGFR1) was quantitated by Duolink 
Image Tool software; 8-15 random fields per sample were analyzed.   
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FGFR1-ER association and localization. PLA was performed using FGFR1 (Abcam, cat. #10646, 
rabbit) and ERα (Santa-Cruz, cat. #8002, mouse) antibodies. Cells (5x104 /well) were seeded in 16-
well chamber slides (Lab-Tek) in triplicate in their respective growth medium and serum starved for 
24 h. PLA (Duolink in situ PLATM; Olink Bioscience, Sweden) was performed to detect FGFR1/ERα 
complexes. To visualize the bound antibody pairs, the Duolink Detection Kit (#DUO92101, Sigma) 
with PLA plus and minus probes for rabbit (anti-rabbit plus, #DUO92002, Sigma) and PLA plus and 
minus probes for mouse (anti-mouse minus, #DUO92004, Sigma) were used according to the 
manufacturer’s protocol. Slides were mounted with the Duolink Mounting Medium and stained with 
DAPI (Sigma 82040-0005). Analysis was performed by confocal microscopy (LSM710, ZEISS) and 
the number of red dots (indicating FGFR1/ERα complexes) was quantitated by the Duolink Image 
Tool software; 8-15 random fields per sample were analyzed. In addition to cells on slides, PLA was 
performed in 5-µm thick sections from paired pre- and post-letrozole FFPE tumor blocks from 
patients in the clinical trial. Tumor sections were de-paraffinized and subjected to antigen retrieval 
by microwave cooking in 0.01M citrate buffer (pH 6.0) at 1000 W for 30 min. After incubation in 
blocking buffer (1X PBS + 10% BSA + 0.3 % Triton X-100), the slides were incubated overnight 
with FGFR1 (Abcam, cat. #10646, rabbit) and ERα (Santa-Cruz, cat. #8002, mouse) antibodies. PLA 
(Duolink in situ PLATM; Olink Bioscience, Sweden) was performed to detect FGFR1/ER 
complexes and their localization. To visualize the bound antibody pairs, the Duolink Detection Kit 
(#DUO92101, Sigma) with PLA plus and minus probes for rabbit (anti-rabbit plus, #DUO92002, 
Sigma) and PLA plus and minus probes for mouse (anti-mouse minus, #DUO92004, Sigma) was 
used according to the manufacturer’s protocol. Slides were mounted with the Duolink Mounting 
Medium and stained with DAPI (Sigma 82040-0005). Analysis was performed by confocal 
microscopy (LSM710, ZEISS) and the number of red dots (FGFR1/ERα complexes) was quantified 
by Duolink Image Tool software; 8-15 random fields per sample were analyzed. 
Viral transduction. FGFR1 wild-type and GFP-expressing lentiviral constructs were generated in 
the pLX302 Gateway vector (Open Biosystems); FGFR1/TK- (K514M) pLX302 was created by site-
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directed mutagenesis by Genewiz (New Jersey, USA). To generate stably-transduced lines, 4 µg of 
the FGFR1, FGFR1/TK– (K514M), and GFP-pLX302 constructs were co-transfected with 3 µg 
psPAX2 (plasmid encoding gag, pol, rev, and Tat genes), and 1 µg pMD2G envelope plasmid (Sigma 
Aldrich) into 293FT cells using Lipofectamine 2000 (Thermo Fisher). 293FT growth media was 
changed 24 h post-transfection; virus-containing supernatants were harvested 48 and 72 h post-
transfection, passed through a 0.45-μm filter, diluted 1:4, and applied to target cells with 8 µg/mL 
polybrene (Sigma Aldrich). Virus-producing cells were selected in 1 µg/mL puromycin.  Empty 
pMXs-puro and pMXs-puro retroviral constructs expressing FGFR1 wild-type and FGFR1/TMD 
FGFR4 were generated by PCR-based cloning by Genewiz. To generate stably-transduced cells, 1 
g of the pMXs-puro retrovirus was co-transfected with 1 g pCMV-VSVG (vesicular stomatitis 
virus surface protein envelope plasmid) into HEKgpIRES cells (HEK293 cells stably harboring a 
gag-pol internal ribosome entry site) using Lipofectamine 2000. Virus harvest and target cell 
infection were performed as above for the lentiviral constructs. 
Gene Expression Analyses. CAMA1 cells were plated in estrogen-free media and treated ± 100 
ng/mL FGF3/19 (Sigma) for 6 h. Cells were harvested and RNA was purified using the RNeAsy kit 
(Qiagen, Valencia, CA); cDNA was generated using High Capacity cDNA Reverse Transcription 
Kits (Applied Biosystems, Carlsbad, CA) followed by analysis of ER pathway genes using the 
Estrogen Receptor PCR Array (Qiagen, PAHS-005Z). RNA sequencing data (see “RNA Sequencing 
and cDNA library construction” below) were aligned to human genome version 19 using the splice-
aware aligner TopHat (v2.0.9), and isoform level expression was quantified using cufflinks. 
Expression levels were normalized across the data set using cuffnorm. We compared genes 
upregulated in FGFR1-amplified vs FGFR1 non-amplified cancers [≥2.0 fold, false discovery rate 
(FDR)-adjusted p≤0.05]. These genes were entered into Gene Set Enrichment Analysis (GSEA) as a 
ranked list. Gene sets with an FDR of <0.01 were considered enriched between FGFR1-amplified 
vs. non-amplified tumors.  
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Chromatin immunoprecipitation/next generation DNA sequencing (ChIP). ChIP was done using 
CAMA1 cells plated in estrogen free media ± 100 ng/mL FGF3 and treated with 2 M lucitanib, 1 
M fulvestrant or the combination. Cells were grown to 80% confluency, washed 3x in ice-cold PBS, 
and then fixed for 10 min at room temperature using 7% formaldehyde. The formaldehyde was 
quenched with 2.5 M glycine; cells were lysed using Farnham lysis buffer first and then with nuclei 
lysis buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA pH 8.0, 1% SDS). The chromatin was sonicated 
using a Covaris LE220 with the following conditions: 35 min at peak power 350, duty factor 15, 200 
cycles/burst, and average power 52.5; 200 μL of the chromatin was saved for input. Sonicated 
chromatin was diluted using ChIP Dilution Buffer (50 mM Tris-HCl pH 8.0, 0.167 M NaCl, 1.1% 
Triton X-100, 0.11% sodium deoxycholate), RIPA-150, protease inhibitors, and sodium butyrate. 
ERα (sc-8002) and FGFR1 (ab10646) antibodies were linked to magnetic anti-mouse and anti-rabbit 
Dynabeads respectively, and then incubated with chromatin for >12 h at 4°C. Immunoprecipitates 
(IPs) were washed with the following buffers (RIPA-150, RIPA-500, RIPA-LiCl, and TE Buffer) for 
5 min each. Chromatin-IPs were eluted from the beads, treated with RNAse A at 65°C with shaking 
for 4 h to reverse crosslinks, followed by Proteinase-K treatment at 55°C for 1 h. Next, DNA was 
purified using phenol-chloroform extraction followed by ethanol precipitation and subsequent 
quantification by Qubit. Standard Illumina ChIPseq library kits were used to build sequencing 
libraries. The resulting libraries were sequenced at Vanderbilt Technologies for Advanced Genomics 
(VANTAGE) Core Resource as SR50 on a HiSeq3000. Each IP was sequenced with a matching input. 
The resulting sequencing files were aligned to human genome version 19 by BWA (Burrows-Wheeler 
Aligner). For each replicate, peaks were called comparing to matched input, using MACS14 and 
default settings. The intersection of peak calls from each replicate was used to define the peak call 
set for each condition. Peaks were assigned to closest genes using annotatePeaks.pl in the HOMER 
analysis suite and heatmaps were generated using ngs.plot. 
Chromatin immunoprecipitation/quantitative PCR (ChIP-qPCR). ChIP was performed in 
CAMA1 cells as described above. DNA was analyzed by real-time qPCR in triplicate with Sso 
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Advanced SYBR Green Supermix (Bio-Rad) in a CFX qPCR machine (Bio-Rad). The fold-
enrichment of ChIP samples was calculated using the 2∆Ct (threshold cycle) method. Ct values for 
ER-ChIP and FGFR1-ChIP samples were normalized to input DNA Ct values, and then 
independently to respective Negative Control Ct values to account for antibody background. Primer 
sequences are listed in Table S1. 
RNA Sequencing and cDNA library construction. Core biopsies were flash frozen in liquid N2 
and stored at -80°C until RNA extraction was performed as described elsewhere (27). Total RNA 
was quantified using the Quant-iT™ RiboGreen® RNA Assay Kit (Invitrogen) and normalized to 4 
ng/μL; 200 ng of each sample were used for library preparation in an automated variant of the 
Illumina Tru Seq™ RNA Sample Preparation protocol (Revision A, 2010). This method uses 
oligo(dT) beads to select mRNA from the total RNA sample and is followed by heat fragmentation 
and cDNA synthesis from the RNA template. The resultant cDNA then goes through library 
preparation (end repair, base ‘A’ addition, adapter ligation, and enrichment) using Broad Institute-
designed indexed adapters for multiplexing. After enrichment, libraries were quantitated with qPCR 
using the KAPA Library Quantification Kit for Illumina Sequencing Platforms and pooled 
equimolarly. The entire process is performed in a 96-well format with all pipetting done by either the 
Agilent Bravo or PerkinElmer JANUS Mini liquid handlers. 
Non-stranded Illumina RNA-sequencing. Pooled libraries were normalized to 2 nM and denatured 
using 0.2 N NaOH prior to sequencing. Flowcell cluster amplification and sequencing were 
performed according to the manufacturer’s protocol using either the HiSeq 2000 v3 or HiSeq 2500. 
Each run was a 76-bp, paired-end run with an eight-base index barcode. Data were analyzed using 
the Broad Picard Pipeline, which includes de-multiplexing and data aggregation. TopHat spliced 
aligner software was used to map sequencing reads and to generate a BAM file for each tumor (28). 
RNAseq GCT files were generated from BAM files using RNA-SeQC (29). 
Xenograft studies. We used two ER+/HER2-/FGFR1-amplified patient-derived xenografts (PDXs). 
PDX T272 (XenTech) required estrogen supplementation in the drinking water (8.5 mg/L estrogen) 
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to grow as tumors in female athymic nude mice (Envigo). The second PDX, TM00368 (Jackson 
Laboratory), was implanted in female ovariectomized SCID/beige mice (Jackson Laboratory) 
implanted with a s.c. 21-day relase, 0.25-mg 17-estradiol pellet (Innovative Research of America). 
Tumors were serially transplanted in athymic or SCID/beige mice under general anesthesia. When 
xenografts reached an average size of ≥200 mm3, mice were randomized to treatment with vehicle, 
lucitanib (10 mg/kg/day p.o. for T272 or 7 mg/kg/day p.o. for TM00368), fulvestrant (5 mg/week 
s.c.) or both drugs (n= 10 per group for T272 and n= 8 per group for TM00368). Tumors diameters 
were measured using calipers twice a week, and volume in mm3 was calculated with the formula: 
volume = width2 x length/2. When tumor volume exceeded 2 cm3 or at end of treatment, mice were 
sacrificed and tumors harvested 1 h after the last dose of lucitanib. Portions of tumors were snap 
frozen or fixed in 10% neutral buffered formalin and embedded in paraffin for subsequent analyses. 
Five-μm paraffinized sections were used for IHC using Y653/54 phosphorylated FGFR1 (Abcam 
#111124) and ERα (Santa Cruz Biotech #8002). Sections were scored by an expert pathologist 
(M.V.E.) blinded to the treatment. 
Immunoprecipitation and immunoblot analyses. Cells were lysed in RIPA buffer (for 
immunoblot) or in NP-40 buffer containing protease and phosphatase inhibitors (for 
immunoprecipitation), and sonicated for 10 sec; debris was separated by centrifugation at 18,000 xg 
for 10 min at 4°C. Protein concentration in the supernatants was measured using the BCA assay 
(Pierce). FGFR1 was precipitated from cell lysates with a FGFR1 C-terminal antibody (Abcam 
#76464) or a FGFR1 N-terminal antibody (Cell Signaling #3472) for 16 h at 4ᵒC. Whole cell lysates 
and immune complexes were separated by SDS-PAGE, transferred to nitrocellulose, and subjected 
to immunoblot analyses as described previously (30) using primary antibodies against ERα, FRS2α 
(Santa Cruz Biotech.), AIF, tubulin, lamin A/C, actin, phosphorylated FRS2α (T436) (Cell Signaling) 
and FGFR1 (Abcam). HRP-conjugated anti-rabbit and anti-mouse were used as secondary antibodies 
(Santa Cruz Biotechnology). Immunoreactive proteins were visualized by enhanced 
chemiluminescence (Pierce, Rockford, IL, USA). Membranes were cut horizontally to probe with 
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multiple antibodies. Blots probed with phospho-antibodies were stripped with Restore Western Blot 
Stripping Buffer (Thermo Fisher Scientific) and re-probed with antibodies to the total protein.  
Membrane, cytoplasmic, nuclear soluble and chromatin-bound fractionation. CAMA1 and 
CAMA1FGFR1 cells were subjected to fractionation using a cell fractionation kit (Thermo Scientific 
#78840) according to the manufacturer’s protocol. Adequacy of fractionation was confirmed by 
immunoblot of cell fractions with antibodies against apoptosis-inducing factor (AIF; plasma 
membrane), tubulin (cytoplasm), lamin A/C (nucleus) and histone H1 (chromatin bound).  
Inhibition of nuclear export. CAMA1 and CAMA1FGFR1 (1x105) cells were grown in chamber 
slides and treated with vehicle or 30 ng/mL leptomycin B for 2 h and then fixed with PBS containing 
3.7% formaldehyde, washed with PBS, permeabilized with PBS containing 0.25% Triton-X-100, 
blocked with PBS containing 10% BSA and 0.1% Tween-20, and incubated overnight with a FGFR1 
(Abcam, cat. #10646, rabbit) primary antibody diluted in blocking solution. Slides were washed and 
incubated with goat-derived Alexa Fluor® 594-conjugated antibodies and mounted with ProLong® 
Gold Antifade mounting media (Life Technologies). IF analysis was performed by confocal 
microscopy (LSM710, ZEISS); nuclear cell fluorescence was quantified by ImageJ using 8-15 
random fields per sample.  
Statistics. Results are representative of 3 independent experiments. Results are expressed as the 
mean, and error bars indicate SEM. A P value of less than 0.05 was considered statistically 
significant. 
Study approval. Animal studies were approved and performed in accordance with the Vanderbilt 
Institutional Animal Care and Use Committee.  
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RESULTS 
FGFR1 amplification and overexpression is associated with endocrine resistance in ER+ breast 
cancer. We studied 72 tumor biopsies from post-menopausal women with clinical stage I-III 
operable, ER+/HER2– breast cancer treated with the aromatase inhibitor letrozole for 2 weeks prior 
to surgery (NCT00651976). Earlier studies have demonstrated that a Ki67 score 2 weeks after 
antiestrogen therapy can be utilized to predict which tumors are endocrine sensitive or resistant, as 
well as their odds of recurrence following adjuvant endocrine therapy (31). We applied these metrics 
to our tumor set and categorized 40 tumors as sensitive [natural log (ln) of post-letrozole Ki67 ≤1.0 
or ≤2.4% tumor cells], 11 tumors as intermediate responders (ln=1.1-1.9 or 2.5-7.3% tumor cells), 
and 21 tumors as resistant (ln ≥2.0 or ≥7.4% tumor cells; Fig. 1A). FGFR1 copy number was 
determined in tumor sections by fluorescence in situ hybridization (FISH). We observed FGFR1 
amplification in 9/21 (43%) resistant tumors compared to 3/40 (7%) sensitive tumors and 1/11 (10%) 
intermediate tumors (resistant vs. intermediate and sensitive tumors; p=0.0011; Fig. 1B). To correlate 
FGFR1 copy number with protein levels, we performed immunohistochemistry (IHC) in tumors from 
the trial. FGFR1 protein levels correlated with gene amplification by FISH. In FGFR1-amplified 
cancers, we observed a significant increase in total and nuclear FGFR1 in post-treatment compared 
to pre-treatment biopsies (p<0.05; Fig. 1C,E). A letrozole-induced increase in both total and nuclear 
FGFR1 was not observed in tumors without FGFR1 amplification (Suppl. Fig. 1A). 
Estrogen deprivation increases nuclear and cytosolic FGFR1 expression. To examine whether 
this same modulation of FGFR1 levels occurred in more controlled experimental models, we tested 
five ER+/HER2– human breast cancer cell lines with and without FGFR1 gene amplification as 
determined by FISH: CAMA1, MDA-MB-134 and HCC1500 cells are FGFR1 amplified while 
MCF-7 and ZR75.1 cells are not (Suppl. Fig. 2A). FGFR1 amplification correlated with FGFR1 
protein levels; MDA-MB-134 and HCC1500 cells express both full-length and cleaved FGFR1 while 
only full-length FGFR1 was detected in CAMA1 cells (Suppl. Fig. 2B). To mirror the acute estrogen 
deprivation induced by letrozole in primary tumors in the clinical trial (32), we cultured the FGFR1-
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amplified cell lines in estrogen-free medium for 4-6 days. This resulted in an increase in FGFR1 
expression in all FGFR1-amplified lines (Fig. 2A). Specifically, we observed an increase in full-
length FGFR1 in CAMA1 cells, of both cleaved and full-length FGFR1 in MDA-MB-134, and only 
the cleaved form in HCC1500 upon estrogen withdrawal. 
To determine whether long-term estradiol deprivation also affected FGFR1 expression, we 
generated three long-term estrogen-deprived (LTED) cell lines as previously described (25): 
CAMA1LTED and MDA-MB-134LTED (FGFR1-amplified) and MCF-7LTED (FGFR1 non-amplified). 
As we had observed with acute estrogen-deprivation, CAMA1LTED and MDA-MB-134LTED cells 
exhibited increased expression of full-length and cleaved FGFR1, respectively, whereas MCF-7LTED 
cells showed a reduction in FGFR1 expression compared to parental MCF-7 cells. The LTED lines 
displayed an increase in ERα levels compared to their parental counterparts (Fig. 2B). 
Immunofluorescence (IF) by confocal microscopy confirmed the increase in total and nuclear FGFR1 
in CAMA1LTED vs. parental cells (Fig. 2C).  
To confirm that FGFR1 localizes to the nucleus we substituted the atypical TMD of FGFR1 
(β-sheet containing polar amino acids) with the typical helical, hydrophobic TMD of FGFR4, 
previously shown to prevent nuclear localization of FGFR1 (18). CAMA1 cells transfected with 
FGFR1 harboring the TMD of FGFR4 (referred to as CAMA1FGFR1/TMD-FGFR4) showed a reduction in 
both nuclear soluble and chromatin-bound FGFR1 relative to CAMA1 cells transfected with wild-
type FGFR1 (Fig. 2D,E). Similar to FGFR1-transfected CAMA1 cells, parental CAMA1 cells also 
exhibited nuclear soluble and chromatin-bound FGFR1 at steady state (Suppl. Fig. 2C). Further, 
treatment with nuclear export inhibitor leptomycin B (33), resulted in an increase in nuclear FGFR1 
as measured by IF in both parental (Fig. 2F) and FGFR1-transfected CAMA1 cells (Suppl. Fig. 2D). 
Knockdown of FGFR1 with siRNA confirmed the specificity of the FGFR1 antibody used for both 
immunoblot and IF analyses (Suppl. Fig. 2E,F). 
FGF3/4/19 expression is upregulated upon estrogen deprivation. Approximately 30-40% of 
FGFR1-amplified breast cancers exhibit amplification of CCND1, FGF3, FGF4 and FGF19 in 
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chromosome 11q12-14 (34). Co-amplification of these genes has been shown to be associated with 
reduced patient survival (22). By interrogating The Cancer Genome Atlas (TCGA), we found that 
among the 13% of breast cancers with FGFR1 amplification, 36% of these tumors also harbor 11q-
12-14 amplification (Suppl. Fig. 3A,B) (35, 36). Outcomes analysis of Kaplan Meier-plotter [breast 
cancer] showed that patients with co-amplification of FGFR1 and CCND1/FGF3/FGF4/FGF19 
treated with antiestrogen therapy exhibit a shorter time to relapse compared to patients without co-
amplified tumors (hazard ratio=1.75; Suppl. Fig. 3C) (37). Based on this analysis, we investigated 
the presence of FGFR1 and 11q12-14 co-amplification in our cohort of patients treated with letrozole. 
In this study, 8 of 9 (90%) FGFR1-amplified tumors exhibited co-amplification of FGF3/4/19 and 
this co-amplification strongly correlated with resistance to estrogen deprivation with letrozole 
(p=0.0001; Fig. 3A). These data suggest that co-amplification of 11q12-14 and FGFR1 plays a 
potentially causal role in resistance to endocrine therapy in hormone-dependent breast cancers. 
We then analyzed 11q12-14 amplification by FISH in ER+ breast cancer cells. All FGFR1-
amplified cell lines exhibited co-amplification of 11q12-14 (Fig. 3B, Suppl. Fig. 4A); FGFR1 non-
amplified MCF-7 cells did not. Supporting a correlation of copy number with gene expression, all 
11q12-14-amplified cell lines expressed markedly higher FGF3/4/19 mRNA levels by qRT-PCR 
compared to MCF-7 cells (Fig. 3C). Similar to the effect on FGFR1 protein levels, 24 h of estrogen 
deprivation increased FGF3/4/19 mRNA expression 1.5- to 2-fold in all FGFR1-amplified cell lines 
(Suppl. Fig. 4B). This increase was even more substantial when we investigated the transcript 
expression of FGF3/4/19 in LTED FGFR1-amplified cells. In contrast, MCF7LTED cells exhibited 
little or no increase in FGF ligands mRNA compared to MCF-7 parental cells (Fig. 3D). 
These results also suggested that an excess of FGFs could accelerate the growth of 
ER+/FGFR1-amplified cells in estrogen-free conditions. To test this, we stimulated estrogen-starved 
CAMA1 cells ± FGF3. Exogenous FGF3 enhanced cell growth compared to unstimulated cells. Both 
treatment with the FGFR1 tyrosine kinase inhibitor (TKI), lucitanib (38) (Fig. 3E), and transfection 
with an FGFR1 siRNA prevented this outgrowth (Fig. 3F). 
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Long-term estradiol deprivation increases the interaction of FGFR1 with ER. The association 
of FGFR1 with other nuclear proteins, such as ribosomal S6 kinase (RSK1) and CREB-binding 
protein (CBP), is required for the ability of nuclear FGFR1 to induce target gene expression in 
medulloblastoma and neuroblastoma cells (39). The interaction between FGFR1 and ERhas been 
reported to mediate lactotroph proliferation in the pituitary gland (40). Thus, we investigated this 
interaction in ER+/FGFR1 amplified breast cancer cells. Immunoprecipitation of FGFR1 from 
MDA-MB-134, CAMA1 and CAMA1LTED whole cell lysates co-precipitated ERα in all three cell 
lines (Fig. 4A). This association was stronger in MDA-134 and CAMA1LTED cells compared to 
parental CAMA1 cells. We next confirmed the FGFR1-ER association in CAMA1 and 
CAMA1LTED nuclear extracts after precipitation with both C-terminal and N-terminal FGFR1 
antibodies (Fig. 4B), consistent with presence of full-length FGFR1 in cell nucleus. To quantitate 
this interaction, we performed proximity ligation assays (PLA). An interaction between FGFR1 and 
ERα was observed in the cytoplasm and nucleus of CAMA1 and CAMA1LTED cells by PLA, 
particularly in in the latter (Fig. 4C,D), in line with the immunoprecipitation experiments. Treatment 
with either lucitanib or fulvestrant reduced FGFR1/ER complexes (Fig. 4E,F), suggesting this 
interaction requires FGFR1 tyrosine kinase (TK) activity. 
To explore further whether the TK function of FGFR1 is required for FGFR1-ERα complex 
formation, CAMA1 cells were transduced with constructs expressing GFP, wild-type FGFR1 or a 
TK dead K514M FGFR1 mutant (FGFR1/TK–). Overexpression of wild-type FGFR1 increased 
detectable FGFR1-ERα complexes while overexpression of FGFR1/TK– decreased them as 
measured by PLA (Fig. 4G,H). Steady-state levels of pFRS2 were upregulated in cells transduced 
with wild-type FGFR1 but not with the FGFR1/TK– mutant (Suppl. Fig. 5A). Importantly, the 
CAMA1FGFR1/TK– cells were not able to grow in the absence of estradiol (Suppl. Fig. 5B,C). These 
data suggest that FGFR1 TK activity is important for the association of FGFR with ER. Finally, we 
observed an increase of FGFR1-ERα complexes in post-letrozole compared to paired pre-letrozole 
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FFPE tumor sections from two breast cancer patients harboring tumor co-amplification of FGFR1 
and 11q12-14 (Fig. 4I,J). 
FGFs/FGFR pathway modulates ER-DNA binding. To evaluate estrogen-independent genomic 
functions of ERα in ER+/FGFR1 amplified cells, we performed chromatin immunoprecipitation 
followed by next-generation sequencing (ChIP-seq) in estrogen-deprived CAMA1 cells ± FGF3. 
Treatment with FGF3 shifted both ER and FGFR1 to new binding sites that were unoccupied in the 
absence of the FGF ligand. (Suppl. Fig. 6A,B). We identified 1120 and 553 regions (peaks) by ERα-
ChIP and FGFR1-ChIP, respectively, that were significantly enriched upon FGF3 treatment. 
Treatment of CAMA1 cells with each fulvestrant or lucitanib alone or in combination reduced ERα 
or FGFR1 DNA binding to these new sites (Fig. 5A,B). These results were validated by ChIP-PCR 
(Suppl. Fig. 6C,D). As shown in Figure 5C,D, ERα and FGFR1 bound to different ERα-related genes, 
but treatment with lucitanib, fulvestrant or the combination reduced or abrogated this binding.  
To identify the functional output of estrogen-independent ERα activity, we classified the 
genes identified by FGFR1 and ERα ChIP-seq using gene set enrichment analysis (GSEA). The top 
enriched gene sets included epithelial mesenchymal transition, STAT5 signaling, estrogen response 
early genes and p53-pathways (all FDR <0.009) after FGFR1 ChIP-seq (Fig. 5E); and estrogen 
response early genes, estrogen response late genes, K-Ras signaling and p53-pathways (all FDR 
<0.0001) after ERα ChIP-seq (Fig. 5F). To apply these findings to primary ER+ breast cancers, we 
performed RNA sequencing analysis on 7 FGFR1-amplified and 25 FGFR1 non-amplified tumors 
treated in the clinical trial with letrozole. The Volcano-plot in Fig. 5G shows that, of >24,000 genes 
analyzed, 280 gene transcripts were increased >2 fold in FGFR1-amplified compared to FGFR1 non-
amplified cancers (p<0.01; red dots in Fig. 5G). The top enriched genes by GSEA in FGFR1 
amplified patients included G2M checkpoint genes, E2F target genes, estrogen response late genes 
and estrogen response early genes (all FDR <0.01; Fig. 5H and Suppl. Fig. 7). These results further 
suggest that the ER pathway is still active in estrogen-deprived (upon letrozole treatment) 
ER+/FGFR1-amplified primary tumors. 
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FGFR1 signaling induces expression of ER-dependent genes. Based on the ChIP-seq results and 
to elucidate further the role of the FGF/FGFR1 axis on ER signaling, we performed a qRT-PCR 
profiling assay including 84 ERregulated genes. FGF3/19 stimulation of estrogen-deprived 
CAMA1 cells induced >2-fold mRNA expression of a subset of ERtarget genes, including TFF1, 
CCND1, THSB1, CTGF, CCL2 and EGR3 (Fig. 6A). Both FGF3 and FGF19 induced EGR3, CCND1 
and THSB1 mRNA; this induction was inhibited by treatment with lucitanib, fulvestrant or the 
combination (Fig. 6B,C), and also by transfection of a TK dead K514M FGFR1 mutant into CAMA1 
cells (Suppl. Fig. 5D). In line with their higher levels of ERFGFR1 and FGF3/4/19 (Figs. 2C, 3D), 
CAMA1LTED cells expressed higher levels of ER-regulate genes than CAMA1 parental cells (Suppl. 
Fig. 8). 
 To support our results with lucitanib were not due to off-target effects of the small molecule, 
we tested the FGFR inhibitor INCB054828 (41). Treatment with INCB054828 also blocked FGF3-
induced pFRS2, CAMA1 cell growth and ER target gene expression (Suppl. Fig. 9A-C).   
Combined blockade of FGFR1 and ERα potently inhibits growth of ER+/FGFR1-amplified 
breast cancers. Treatment with fulvestrant and lucitanib reduced the expression of ERα dependent 
genes in ER+/FGFR1-amplified breast cancer cells (Fig. 6). Thus, we next examined whether FGFR1 
and/or ER inhibitors would have an effect on tumor cell growth. Treatment with the combination 
of lucitanib and fulvestrant suppressed CAMA1 colony formation in 3D-matrigel significantly more 
potently than each drug alone (Fig. 7A,B). Western blot analysis of lysates from cells treated for 6 h 
showed that the only the combination simultaneously reduced levels of pFRS2, pERK1/2 and ERα 
(Fig. 7C). We next examined the effect of these drugs against two ER+/HER2–/FGFR1-amplified 
patient-derived xenografts (PDXs), T272 and TM00368 (Fig. 7D). Ovariectomized mice with 
established xenografts (≥250 mm3) were treated with vehicle, lucitanib, fulvestrant or both drugs. 
PDX T272 but not PDXTM00368 required brief estrogen supplementation to generate tumors. In 
mice bearing PDX T272, the dose of lucitanib was reduced from 10 to 7 mg/kg/day after 3 weeks of 
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therapy due to toxicity in both lucitanib-containing arms. Mice with TM00368 PDXs were treated 
with 7 mg/kg/day lucitanib. Treatment with the combination of fulvestrant and lucitanib inhibited 
growth of both PDXs more potently than either drug alone (Fig. 7E and Suppl. Fig. 10A). All mice 
bearing TM00368 xenografts exhibited a ≥50% reduction in tumor size from baseline after 3 weeks 
of treatment with fulvestrant/lucitanib (Fig. 7F). Biomarkers of response were assessed by IHC in 
TM00368 tumors harvested at the completion of therapy. Treatment with the combination of 
lucitanib plus fulvestrant markedly reduced detectable levels of Y653/4 phosphorylated FGFR1 and 
total ER (Fig. 7G,H). FGFR1 antibody pulldowns of tumor lysates from vehicle- and lucitanib-
treated mice co-precipitated ER. This was not observed in tumors treated with fulvestrant or the 
combination Fig No change in mouse weight was observed in any of the treatment arms (Suppl. 
Fig. 10B,C). 
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DISCUSSION 
We report herein a novel mechanism by which FGFR1 amplification confers resistance to 
antiestrogen therapy in ER+ breast cancers. In a cohort of post-menopausal patients treated with the 
aromatase inhibitor letrozole, cancers with FGFR1 and FGF3/4/19 amplification retained tumor cell 
proliferation, suggesting aberrant FGFR1 signaling is associated with resistance to estrogen 
deprivation. Short and long-term estrogen deprivation increased total and nuclear FGFR1 and FGF 
ligand expression in ER+/FGFR1-amplified breast cancer cells and primary tumors. This was 
associated with an increase in nuclear FGFR1/ER complexes and maintenance of estrogen-
independent transcription of ER-responsive genes. The interaction between FGFR1 and ER was 
blocked by a kinase-dead FGFR1 mutant or by FGFR tyrosine kinase inhibitors. ChIP-seq analysis 
of FGF-stimulated FGFR1-amplified cells showed binding of FGFR1 and of ER to DNA, which 
was inhibited by the FGFR TKI lucitanib and by the ER downregulator fulvestrant, respectively, 
suggesting a possible inter-dependence between FGFR1 and ER at transcription start sites. Of note, 
RNA-seq data from ER+/FGFR1-amplified tumors from patients treated with letrozole suggested the 
ER pathway is still active (Fig.5G,H), thus providing a plausible explanation for maintenance of 
proliferation in these estrogen-deprived cancers. Finally, dual pharmacological inhibition of FGFR1 
and ERα potently inhibited growth of ER+/FGFR1-amplified breast cancer cells and PDX models, 
supporting the clinical development of this combination in patients with this subtype of breast cancer. 
The association of FGFR1 with other nuclear proteins is required for the ability of nuclear 
FGFR1 to induce target gene expression in other cancers (39). Since FGFR1 inhibition reduced the 
transcription of ER related genes, we speculated the previously reported transcriptional function of 
FGFR1 (16, 19, 39, 42) may play a role in resistance to estrogen deprivation. Of note, we precipitated 
both FGFR1 and ER with C-terminal and N-terminal FGFR1 antibodies from FGFR1-amplified 
CAMA1 cell nuclei (Fig. 4B), suggesting that full-length FGFR1 associates with ER in the nucleus. 
These findings were supported by PLA and confocal microscopy studies (Fig. 4C). Inhibition of 
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FGFR1 TK activity with lucitanib and expression of a TK dead K514M FGFR1 mutant into CAMA1 
cells reduced ERα-dependent gene transcription (Fig. 6B-C and Suppl. Fig. 5D) and inhibited the 
association of FGFR1 with ER (Fig. 5E-H). Taken together, these data support a novel TK-
dependent role of nuclear FGFR1 on ER-dependent gene transcription in estrogen-independent 
ER+/FGFR1-amplified breast cancers.  
To the best of our knowledge, this is the first report of a physical association of FGFR1 and 
ER associated with antiestrogen resistance. It follows studies supporting both the nuclear 
localization and nuclear function of FGFR1. FGFR1 can enter the nucleus by retrograde transport 
from the endoplasmic reticulum lumen to the cytosol via Sec61p channels before endoplasmic 
vesicles deliver the receptor to the plasma membrane (17, 43). This process is possible because of 
the atypical TMD of FGFR1, which consists of non-polar amino acid chains interrupted by polar 
regions in a β-sheet structure, thus allowing mobilization of the receptor out of the membrane (17, 
43). Consistent with these data, CAMA1 cells transfected with FGFR1 harboring the TMD of FGFR4 
showed a reduction in both nuclear soluble and chromatin-bound FGFR1 relative to CAMA1 cells 
transfected with wild type FGFR1 (Fig. 2E).  
Cell surface biotinylation assays show that nuclear FGFR1 can also originate from the cell 
surface (44), suggesting FGFR1 is internalized and traffics to the nucleus via endosomal pathways. 
Indeed, FGFR1 and FGFR2 can translocate to the nucleus following ligand stimulation in pancreatic 
stellate cells; this process requires the interaction of FGFR1 with nuclear import proteins, like 
importin β (15, 45). Once in the nucleus, FGFR1 has been shown to regulate gene transcription (16, 
19, 39, 42). Nuclear targeting of FGFR1 by substituting its signal peptide for a nuclear localization 
sequence (NLS) is sufficient to initiate DNA synthesis and transcription of c-Jun, an activator of 
cyclin D1. Removal of the kinase region of nuclear-targeted FGFR1 ablates this effect (46). These 
data suggest the TK function of FGFR1 is necessary for its transcriptional role, consistent with our 
data from ER+/FGFR1-amplified breast cancer cells shown herein. 
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In summary, we have identified a mechanism by which amplified FGFR1 can sustain an 
estrogen-independent tumorigenic population. We propose this mechanism explains, in part, the 
limited effects of estrogen deprivation on ER+/ FGFR1-amplified breast cancers in the clinical trial 
with letrozole. Based on these data, we propose combinations of ERα and FGFR antagonists should 
be tested in patients with ER+/FGFR1-amplified breast cancer.  
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Figure Legends 
 
Figure 1. FGFR1 amplification and overexpression associate with endocrine resistance in ER+ 
breast cancer. A, Clinical trial schema: Patients with stage I-III, ER+/HER2– breast cancer were 
treated with letrozole for 10-21 days. Surgery was performed following treatment and tumor response 
was categorized by calculating the natural log (ln) of the post-letrozole Ki67 score as determined by 
IHC analysis. B, FGFR1 amplification, determined by FISH, was significantly associated with 
resistant vs. intermediate or sensitive tumors (p<0.05, Fisher’s t-test). C-E, Tumor sections were 
stained for FGFR; the percent of FGFR1-positive tumor cells and staining intensity were assessed in 
both the cytoplasmic and nuclear compartments by a blinded expert breast pathologist (M.V.E.) to 
generate a H-score (D). The percent of cytoplasmic and nuclear FGFR1+ tumor cells and their 
staining intensity were assessed by a blinded expert pathologist (M.V.E.) to generate a H-score. Total 
and nuclear FGFR1 H-scores are shown in C and E, respectively (Fisher’s t-test).  Both total and 
nuclear FGFR1 staining was higher in post-treatment tumor sections. 
Figure 2. Estrogen deprivation increases nuclear and cytosolic FGFR1 expression. A, 
Immunoblot analysis of lysates from CAMA1, HCC1500 and MDA-MB-134 cells exposed to short-
term estrogen deprivation up to 6 days revealed an increase in FGFR1 expression over time. 
HCC1500 cells showed increased expression of the cleaved form of FGFR1. B, Immunoblot analysis 
of parental and LTED ER+ cell lines following 24 h of estrogen deprivation revealed an increase in 
FGFR1 and ERα in FGFR1-amplified CAMA1LTED and MDA-MB-134LTED cells but not in FGFR1 
non-amplified MCF-7 cells. C, Proximity ligation assay (PLA) to detect FGFR1 expression. Analysis 
of red, amplified loci by confocal microscopy confirmed immunoblot and FISH results in that 
CAMA1LTED cells harbor more cytosolic and nuclear FGFR1 compared to CAMA1 parental cells. 
Each bar in the graph to the right of the PLA image represents the mean nuclear fluorescent signals 
± SD of 3 wells. D, CAMA1 cells stably transduced with constructs encoding wild-type FGFR1 
(CAMA1FGFR1) or FGFR1 in which the TMD has been substituted with the FGFR4 TMD 
(CAMA1FGFR1/TMD-FGFR4) were lysed for immunoblot analysis with FGFR and tubulin antibodies. E, 
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Membrane, cytoplasmic, nuclear soluble and chromatin-bound fractions of CAMAFGFR1 and 
CAMAFGFR1/TMD-FGFR4 cells demonstrates that substitution of the FGFR1 TMD with the TMD of 
FGFR4 reduces detectable nuclear FGFR1, particularly the chromatin-bound fraction in 
CAMA1FGFR1/TMD-FGFR4 cells compared to CAMA1FGFR1 cells. Apoptosis-inducing factor (AIF), 
tubulin, lamin A/C and histone H1 antibodies were used as controls for the cell fractionation. F, 
Immunofluorescence (IF) was performed in CAMA1 cells treated with vehicle or 30 ng/mL 
leptomycin B for 2 h. Nuclear localization of FGFR1 was detected by confocal microscopy. Each bar 
represents the mean nuclear fluorescent signals ± SD of 3 wells.   
Figure 3. FGF3/4/19 expression is upregulated upon estrogen deprivation. A, FISH analysis of 
primary tumor sections showed co-amplification of FGFR1 and 11q12-14 mainly in letrozole-
resistant vs. intermediate and sensitive cancers (p=0.0001, Fisher’s t-test). B, Co-amplification of 
11q12-14 was observed in ER+/FGFR1-amplified cell lines MDA-MB-134, CAMA1 and HCC1500; 
the Y axis shows the 11q12-14:Chr.11 ratio. C, Relative transcript expression of FGF3/4/19 in the 
indicated cell lines was determined by qPCR as described in Methods. D, Transcript levels of 
FGF3/4/19 were higher in FGFR1-amplified LTED cells (CAMA1 and MDA-MB-134) but not in 
FGFR1 non-amplified MCF-7LTED cells compared to their parental counterparts (Fisher’s t-test). E, 
CAMA1 cells were treated with 100 ng/mL FGF3 ± 2 μM lucitanib in estrogen-free medium. After 
15 days, plates were washed and stained with crystal violet and their imaging intensity was quantified 
by spectrophotometric detection. Representative images and quantification of the integrated intensity 
values as % of vehicle-treated controls are shown (Fisher’s t-test). F, CAMA1 cells were plated in 
100-mm dishes and transfected with FGFR1 or control siRNAs as described in Methods. Medium 
containing 100 ng/mL FGF3 was replenished every 3 days. Seven days later, monolayers were 
harvested and cell counts determined using a Coulter Counter. Each bar in the left panel represents 
the mean cell number ± SD of triplicate wells (Fisher’s t-test). FGFR1 knockdown was confirmed by 
immunoblot analysis of cell lysates from plates treated identically in parallel (right panel). 
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Figure 4. Long-term estradiol deprivation increases the interaction of FGFR1 with ER. A, 
FGFR1 was precipitated from MDA-MB-134, CAMA1 and CAMA1LTED cell lysates; immune 
complexes were separated by SDS-PAGE and subjected to immunoblot analysis with an ER 
antibody. CAMA1LTED cells exhibited greater levels of FGFR1-ERα co-immunoprecipitation 
compared to CAMA1 cells. B, FGFR1 was precipitated from CAMA1 and CAMA1LTED nuclear 
extracts with C-terminal (Abcam) and N-Terminal (Cell Signaling) FGFR1 antibodies; immune 
complexes were separated by SDS-PAGE and analyzed by ER immunoblot. C-D, PLA of 
CAMA1LTED cells showed greater nuclear co-localization of FGFR1 and ERα compared to parental 
CAMA1 cells. PLA foci/cell are quantified in D. E-F, CAMA1LTED cells were treated with 2 µM 
lucitanib or 1 µM fulvestrant for 6 h. Monolayers were subjected to PLA as described in Methods. 
Quantification of FGFR1-ERα complexes as PLA signals/cell is shown in (F). Each bar represents 
the mean ± SD of 3 wells. G-H, CAMA1 cells were stable transfected with expression vectors 
encoding GFP, FGFR1 and FGFR1/TK– (K514M TK mutant), as described in Methods, and then 
plated in chamber slides followed by PLA. Quantification of FGFR1-ERα complexes as PLA 
signals/cell is shown in (H). Each bar represents the mean ± SD of 3 wells. I-J, Paired pre- and post-
letrozole primary tumor sections were subjected to PLA as described in Methods. Post-letrozole 
tumor cells exhibited more FGFR1-ERα complexes compared to pre-treatment tumor cells as 
quantitated in J. Each bar represents the mean PLA signals/cell ± SD of 20 cells counted in each of 
4 high-power fields.  
Figure 5. Identification of FGF-sensitive ER and FGFR1 genomic binding sites. A-B, CAMA1 
cells were plated in estrogen-free medium and stimulated with 100 ng/mL FGF3 for 6 h in the 
presence of 1 µM fulvestrant, 2 µM lucitanib or the combination. Cells were harvested and subjected 
to ChIP-seq as described in Methods. Shown are heatmaps generated from ChIP-seq analysis of ERα 
(A) and FGFR1 (B) DNA binding. Treatment with fulvestrant, lucitanib or the combination reduced 
binding of ERα (A) or FGFR1 (B) binding to DNA. Heatmaps represent the mean of two different 
experiments. C-D, Heatmaps of ChIP-seq data showing the effects of fulvestrant, lucitanib or the 
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combination on DNA/ERα-associated (C) and DNA/FGFR1-associated (D) genes, respectively, as 
shown in A-B. E-F, Gene set enrichment analysis (GSEA) of FGFR1- and ERα-associated genes. 
Numbers to the right of each bar represent the False Discovery Rate (FDR) q-value. G, Volcano plot 
analysis of differentially expressed genes in tumors from patients treated with letrozole in the clinical 
trial. Each data point represents the ratio of the average expression for a particular gene in FGFR1-
amplified tumors (n=7) vs. FGFR1 non-amplified tumors (n=25). The red dots in the Volcano plot 
represent genes that are significantly up- or down-regulated >2-fold with p<0.01. H, GSEA of 
significantly enriched genes in FGFR1-amplified relative to FGFR1 non-amplified tumors showed 
that ER-related pathways are still active in estrogen-deprived (by letrozole treatment) ER+/FGFR1-
amplified primary tumors (G). Numbers to the right of each bar represent the FDR q-value.  
Figure 6. Treatment with FGFs induces expression of ERα-dependent genes. A, CAMA1 cells 
were plated in estrogen-free medium and treated with 100 ng/mL FGF3/19 for 6 h. At this time, cells 
were harvested and RNA prepared and analyzed for mRNA expression changes in ERα pathway 
genes using the RT2 Profiler Estrogen Receptor Signaling PCR Array (Qiagen). B-C, CCND1, EGR3 
and THSB1 mRNA expression was confirmed by qRT-PCR in CAMA1 cells treated with FGF3 (B) 
or FGF19 (C) for 6 h ± 2 M lucitanib or 1 M fulvestrant. Each bar represents the mean CCND1, 
EGR3 and THSB1 transcript levels ± SD (Fisher’s t-test). 
Figure 7. Combined blockade of FGFR1 and ERα potently inhibits growth of ER+/FGFR1-
amplified breast cancers. A-B, CAMA1 cells were cultured in 3D Matrigel as described in Methods 
and treated with vehicle, 2 M lucitanib, 1 M fulvestrant or the combination. After 15 days, images 
were captured from 3 different fields using a CK40 microscope. Quantitation of representative 
images is shown in (B). Each bar represents the fold change in colony number relative to vehicle ± 
SD of three replicate wells repeated twice (Fisher’s t-test). C, CAMA1 cells in were treated as in A 
& B for 6 h, after which lysates were prepared and subjected to immunoblot analyses with the 
indicated antibodies. E, ER+/HER2–/FGFR1-amplified TM00368 PDXs were established in 
ovariectomized SCID/beige mice implanted with a s.c. 21-day relase, 0.25-mg 17-estradiol pellet. 
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Once tumors reached ≥200 mm3, mice were randomized to treatment with vehicle, fulvestrant (5 
mg/kg/week), lucitanib (7 mg/kg/day), or both drugs for 3 weeks. Each data point represents the 
mean tumor volume in mm3 ± SD (n=8 per arm; ANOVA test). F, Bar graph showing the % change 
in volume in individual TM00368 PDXs after three weeks of treatment relative to tumor volumes on 
day 0 (baseline). G-H, TM00368 tumors were harvested at the end of treatment. FFPE tumor sections 
were prepared and subjected to IHC with Y653/4 phosphorylated FGFR1 and ER antibodies as 
described in Methods. The percent of phospho-FGFR1+ and ER+ tumor cells and their staining 
intensity was assessed by an expert breast pathologist (M.V.E.) blinded to treatment to generate an 
H-score. Nuclear phospho-FGFR1 and ER H-scores are shown Fisher’s t-test). I, FGFR1 was 
precipitated from lysates of TM00368 tumors harvested at the end of treatment; immune complexes 
were separated by SDS-PAGE and subjected to immunoblot analysis with the indicated antibodies. 
Bottom two lanes show FGFR1 and ER content in lysates before i.p. 
 
 







Supplementary Figures 
Supplementary Figure 1. Effect of letrozole on expression and localization of FGFR1 in 
primary breast tumors without FGFR1 amplification. FGFR1 gene copy number and protein 
expression were determined by FISH (FGFR1:Chr.8 ratio, 100x magnification) and IHC, 
respectively. Total (A) and nuclear (B) FGFR1 expression was decreased in post-letrozole 
compared to paired pre-letrozole patient tumors (***p<0.001 vs. pre-letrozole, Fisher’s t-test). 
Representative IHC and FISH images are shown in B. 
 
 
 
  
Supplementary Figure 2. FGFR1 amplification and protein expression in ER+ human breast 
cancer cell lines. A, Table depicts the FGFR1:Chr.8 ratio in a panel of ER+ human breast cancer 
cell lines as determined by FISH. MDA-MB-134, CAMA1, and HCC1500 cells are FGFR1 
amplified, whereas MCF7 and ZR75.1 cells are not. B, Immunoblot analysis of cell lysates 
displays the relative content of the full-length and cleaved forms of FGFR1, FRS2, phosphorylated 
FRS2 and ERα, using actin as a loading control. C, Membrane, cytoplasmic, nuclear and 
chromatin-bound fractions of CAMA1 cells revealed full-length FGFR1 in both nuclear soluble 
and chromatin-bound fractions. Apoptosis-inducing factor (AIF), tubulin, lamin A/C and histone 
H1 antibodies were used as controls. D, Immunofluorescence analysis was performed in 
CAMA1FGFR1 cells treated with vehicle or 30 ng/mL leptomycin B for 2 h. Nuclear localization of 
FGFR1 was detected by confocal microscopy. Each bar represents the mean nuclear fluorescent 
signals ± SD of 3 wells. E-F, PLA was used to assess FGFR1 expression in CAMA1 cells 
transfected with FGFR1 siRNA or a negative (scrambled) control as described in Methods. Cell 
lysates from identically-treated parallel plates were prepared and subjected to immunoblot analysis 
with the indicated antibodies to confirm siRNA-mediated FGFR1 knockdown. 
 
  
 Supplementary Figure 3. Breast cancers with co-amplification of FGFR1 and 11q12-14 genes 
exhibit decreased time to recurrence. A, Tile plot of ER+ breast cancers in TCGA (Cell 2015) 
with co-amplification of FGF3/4/19 and CCND1 on chr.11q12-14 and of FGFR1 on chr. 8p11. B, 
Analysis of TCGA breast whole exome sequencing (WES) data showed significant co-occurrence 
of FGFR1 and FGF3/4/19 amplification (n=594 samples; p<0.001, Fisher’s t-test). C, Kaplan 
Meier plot from the KMPLOT gene expression database showing the probability of relapse for 
patients with ER+ breast cancer treated with endocrine therapy comparing the high and low tertiles 
of both FGFR1 and FGF3/4/19 mRNA expression by microarray. Patients in the high tertile tended 
toward a shorter relapse-free survival compared to patients in the low tertile (HR 1.75, p =0.069). 
 
  
Supplementary Figure 4. Estrogen deprivation upregulates FGF ligand expression in 
ER+/FGFR1-amplified cells. A, 11q12-14 amplification was determined in a panel of ER+ cell 
lines by FISH using CCND1 and chromosome 11 centromere probes. FGFR1-amplified MDA-
MB-134, CAMA1, and HCC1500 cell lines exhibited co-amplification at 11q12-14. B, MDA-MB-
134, CAMA1 and HCC1500 cells were cultured in full media or estrogen-free medium for 24 h. 
RNA was collected at that time and subjected to mRNA expression analysis by qPCR as described 
in Methods. Estrogen-deprivation (grey bars) resulted in an increase in FGF3/4/19 transcript levels 
compared to non-deprived conditions (black bars) (*p<0.05 vs. control, Fisher’s t-test). 
 
  
Supplementary Figure 5. A, CAMA1GFP, CAMA1FGFR1/WT and CAMA1FGFR1/TK– cells were 
treated with 100 ng/mL FGF3 for 6 h and then lysed for immunoblot analysis with the indicated 
antibodies. B-C, CAMA1GFP and CAMA1FGFR1/TK– cells were seeded in 6-well plates in estrogen-
free media. After 14 days, monolayers were stained with crystal violet. Images of the plates were 
obtained (B) and image intensity was quantitated as described in Methods. Quantitation is shown 
in (C; ***p<0.001 vs. CAMA1GFP, Fisher’s t-test). D, CAMA1GFP ± 2 M lucitanib and 
CAMA1FGFR1/TK– cells were plated in estrogen-free medium and treated with 100 ng/mL FGF3 for 
6 h. At this time, cells were harvested and RNA was prepared and analyzed for THBS1, CCND1, 
CCL2 and EGR3 mRNA changes by qRT-PCR. Each bar represents the mean transcript level ± SD 
(*p<0.05, **p<0.01, ***p<0.001 vs. CAMA1GFP, Fisher’s t-test).  
 
  
Supplementary Figure 6. FGFs induce ERα and FGFR1 DNA binding. A-B, Heatmaps from 
ChIP-seq analysis of estrogen-deprived CAMA1 cells ± 100 ng/mL FGF3 (6 h) showing ERα (A) 
and FGFR1 (B) DNA binding peaks. The heatmaps represent the mean of two different 
experiments. C-D, CAMA1 cells were plated in estrogen-free media and treated with vehicle, 2 
µM lucitanib, 1 μM fulvestrant or the combination for 6 h. ChIP was performed with ERα (C) or 
FGFR1 (D) antibodies. Primers to amplify FGFR1 or ERα binding regions were used in qPCR to 
determine fold enrichment relative to input. Two-tailed Student’s unpaired t test was performed to 
compare mean signal amplification in cells treated with vehicle vs. lucitanib plus fulvestrant. Each 
bar represents the mean fold-enrichment in ERα-ChIP (C) or FGFR1-ChIP (D) ± SD of two 
independent experiments with three technical replicates each. 
 
 
 
Supplementary Figure 7. ER+/FGFR1-amplified tumors exhibit differential gene expression 
compared to ER+/FGFR1 non-amplified breast cancers. Heatmap of G2M checkpoint genes, 
E2F target genes and estrogen-response genes identified by Gene Set Enrichment Analysis 
(GSEA) in ER+/FGFR1-amplified vs. ER+/FGFR1 non-amplified breast tumors from patients 
treated with letrozole in the clinical trial. 
   
 
 
Supplementary Figure 8. Treatment with FGFs induces expression of ERα-dependent genes. 
CAMA1 and CAMA1LTED cells were plated in estrogen-free medium and treated with 100 ng/mL 
FGF3 for 6 h. At this time, cells were harvested and RNA prepared and analyzed for mRNA 
expression changes in ERα pathway genes using the RT2 Profiler Estrogen Receptor Signaling 
PCR Array (Qiagen). 
 
 
  
 Supplementary Figure 9. A, CAMA1 cells were treated with 100 ng/mL FGF3 ± 1 μM 
INCB054828 in estrogen-free medium. After 15 days, plates were washed and stained with crystal 
violet and their imaging intensity was quantified as described in Methods. Representative images 
and quantification of the imaging intensity values as % of vehicle-treated controls are shown 
(**p<0.01 vs. controls, Fisher’s t-test). B, CAMA1 cells in identically treated parallel plates were 
treated for 6 h after which lysates were prepared and subjected to immunoblot analyses with the 
indicated antibodies. C, CAMA1 ± 1 M INCB054828 were plated in estrogen-free medium and 
treated with 100 ng/mL FGF3 for 6 h. At this time, cells were harvested and RNA was prepared 
and analyzed for THBS1, CCND1, CCL2 and EGR3 mRNA changes by qRT-PCR. Each bar 
represents the mean transcript level ± SD (*p<0.05, **p<0.01, ***p<0.001 vs. CAMA1GFP, 
Fisher’s t-test).  
 
  
 Supplementary Figure 10. A, ER+/HER2–/FGFR1-amplified T272 PDX tumors were 
established in female athymic nude mice supplemented with estrogen 8.5 mg/L in the drinking 
water. Once tumors reached ≥200 mm3, mice were randomized to treatment with vehicle, 
fulvestrant (5 mg/kg/week), lucitanib (10 mg/kg/day), or both drugs for 5 weeks. Each data point 
represents the mean tumor volume in mm3 ± SD (n=10 per arm; *p<0.05 vs. lucitanib; Fisher’s t-
test). B-C Weight of SCID/beige mice bearing T272 or TM00368 PDX tumors during treatment 
with vehicle, fulvestrant, lucitanib or the combination for a total of 7 and 3 weeks, respectively. 
The number of mice in each treatment arm is shown in parentheses. Each data point represents 
mean weight in grams ± SD.   
 
 
 Table S1. Primer sequences used for ChIP-qPCR. 
Genomic Region Fwd primer Rev primer 
38477209:38479862 TGGGTGTCTCTTGCTTCGTC CATGATGTGTGCTGGAGGGT 
38477209:38479862 AACCTTCAGCCCAGGAATCG ATCTGCACAGTGGGTCACAG 
17271502:17274328 GCCCCGCATAAAGAAAGCAG AGCAAAAGCCGCAGTAGAGT 
  
 
 
 
 
 
 
